JSP Pharmaceutical Manufacturing (Thailand) Public Co., Ltd. (JSP.BK)
Bangkok, TH
Established in 2005 and headquartered in Bangkok, Thailand, JSP Pharmaceutical Manufacturing (Thailand) Public Co., Ltd. specializes in providing contract manufacturing services. The company produces a diverse range of products, including dietary supplements, cosmetics, herbal remedies, nutritional products, and pharmaceutical goods within Thailand. Beyond manufacturing, JSP also offers comprehensive support services, encompassing research and development, packaging solutions, and regulatory registration assistance for both pharmaceuticals and dietary supplements. Additionally, the firm manufactures various cleaning products, such as hand sprays and specialized pharmaceutical sanitizers.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | -1.12% | -6.84% | -14.90% | +8.59% | -6.84% | -1.67% | -46.36% | -82.82% | -82.82% | -82.82% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Packaged Foods: +4.4%+22.5% ★ Q1'26: -11.6% (vs Q1'25)
-
EPS growth Packaged Foods: +14.6%+1,373.7% ★ Q1'26: -93.7% (vs Q1'25)
-
FCF margin FCF growth · Packaged Foods: +15.9%-1.0% Q1'26: -9.9% (vs Q1'25)
-
EBIT margin Packaged Foods: +7.9%+6.7% Q1'26: +0.2% (vs Q1'25)
-
ROIC Packaged Foods: +7.0%+3.2% Q1'26: +0.1% (vs Q1'25)
-
Share dilution Packaged Foods: +0.0%+0.0% Q1'26: 0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Packaged Foods: 0.19×2.77× Q1'26: 5.94× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-28 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-27 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-26 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-25 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-22 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-21 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-20 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-19 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-18 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-15 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-14 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-13 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-12 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-11 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-08 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 4/5 | 4/5 |
| 2026-05-07 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 4/5 | 4/5 |
| 2026-05-06 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 4/5 | 4/5 |
| 2026-05-05 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-30 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-29 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-28 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-27 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-24 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-23 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-22 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-21 | B+ | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-20 | B+ | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-17 | B+ | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-16 | B+ | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Danaisuan Kunarojanasombhat | Plant Senior Manager | — | male |
| Jirada Daengprasert | CFO, EVP of Finance & Accounting, EVP of Manufacturing, Operations(Acting), Co. Secretary & Director | — | female |
| Kriangkrai Rungruangthaweekul | Head of Investor Relations, Head of Compliance & Vice President of Finance | — | male |
| Nongnuch Cheawpattayakorn | Quality Assurance Senior Manager | — | female |
| Pissanu Daengprasert | President & Director | — | male |
| Sirisak Manitkunakarn | Head of Internal Audit | — | male |
| Sittichai Daengprasert | Group President & Director | — | male |
| Sorasit Daengprasert | Executive Vice President of Sales & Marketing and Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for JSP.BK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
